BridgeBio Oncology Therapeutics develops novel small molecule inhibitors targeting the active states of RAS proteins and the RAS-PI3Kα interaction. Their pipeline aims to overcome limitations of current cancer therapies by maximizing target inhibition and addressing resistance mechanisms for RAS and PI3Kα-driven cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with cancers driven by RAS mutations or PI3Kα activation have limited treatment options because existing therapies often target only a subset of mutant forms or the inactive (OFF) state, resulting in incomplete pathway inhibition and suboptimal clinical outcomes.
Solution
BridgeBio Oncology Therapeutics applies deep expertise in RAS signaling to design small‑molecule inhibitors that directly block the active (ON) conformation of KRAS and downstream PI3Kα signaling. By focusing on the ON state, the company seeks to achieve more complete pathway suppression across a broad spectrum of KRAS mutants, including those resistant to current inhibitors. The approach combines structure‑guided drug design with selective targeting of RAS‑driven PI3K activation, aiming to deliver therapies that can halt tumor growth in patients whose cancers are driven by these pathways. Preclinical programs are built to validate potency, selectivity, and pharmacokinetic properties before advancing to clinical testing.
Target Audience
Primary customers are oncology clinicians and healthcare systems treating patients with KRAS‑mutant or PI3Kα‑driven solid tumors, as well as pharmaceutical partners seeking to co‑develop RAS‑targeted therapeutics.
Features
- Structure‑based design of inhibitors that bind the active (GTP‑bound) KRAS conformation
- Broad coverage of multiple KRAS mutant alleles, including both common and rare variants
- Selective inhibition of PI3Kα activation that is specifically driven by mutant RAS signaling
- Dual‑state targeting strategy to suppress signaling from both ON and OFF KRAS states
- Integrated pharmacology platform to optimize potency, selectivity, and drug‑like properties